# Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants

> **NCT04535141** · PHASE3 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 91 (actual)

## Conditions studied

- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** Olanzapine 5 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04535141
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-18
- **Primary completion:** 2022-04-11
- **Final completion:** 2022-04-11
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2023-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04535141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04535141, "Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04535141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*